| 000 | 01895 a2200529 4500 | ||
|---|---|---|---|
| 005 | 20250518000315.0 | ||
| 264 | 0 | _c20190520 | |
| 008 | 201905s 0 0 eng d | ||
| 022 | _a1600-0609 | ||
| 024 | 7 |
_a10.1111/ejh.13175 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aNielsen, Lene Kongsgaard | |
| 245 | 0 | 0 |
_aClarithromycin added to bortezomib-cyclophosphamide-dexamethasone impairs health-related quality of life in multiple myeloma patients. _h[electronic resource] |
| 260 |
_bEuropean journal of haematology _cJan 2019 |
||
| 300 |
_a70-78 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xadverse effects |
| 650 | 0 | 4 |
_aBortezomib _xadministration & dosage |
| 650 | 0 | 4 |
_aClarithromycin _xadministration & dosage |
| 650 | 0 | 4 | _aClinical Protocols |
| 650 | 0 | 4 |
_aCyclophosphamide _xadministration & dosage |
| 650 | 0 | 4 |
_aDenmark _xepidemiology |
| 650 | 0 | 4 |
_aDexamethasone _xadministration & dosage |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aInduction Chemotherapy |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aMultiple Myeloma _xdiagnosis |
| 650 | 0 | 4 | _aNeoplasm Staging |
| 650 | 0 | 4 | _aQuality of Life |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aKlausen, Tobias Wirenfeldt | |
| 700 | 1 | _aJarden, Mary | |
| 700 | 1 | _aFrederiksen, Henrik | |
| 700 | 1 | _aVangsted, Annette Juul | |
| 700 | 1 | _aDo, Trung | |
| 700 | 1 | _aKristensen, Ida Bruun | |
| 700 | 1 | _aFrølund, Ulf Christian | |
| 700 | 1 | _aAndersen, Christen Lykkegaard | |
| 700 | 1 | _aAbildgaard, Niels | |
| 700 | 1 | _aGregersen, Henrik | |
| 773 | 0 |
_tEuropean journal of haematology _gvol. 102 _gno. 1 _gp. 70-78 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1111/ejh.13175 _zAvailable from publisher's website |
| 999 |
_c28849976 _d28849976 |
||